Fridays review

Fridays looks, at first, like exactly what a low-dose reader wants. It sells a genuine, named microdose product — its own navigation has a Microdosing tab, the page describes weekly injections or daily oral tablets, and both products carry plain unconditional monthly prices with no code and no term attached. It also sells the ordinary full-dose versions of the same two molecules. Put the two pages side by side and the microdose semaglutide costs more than twice what the standard semaglutide headline says, while the microdose tirzepatide costs exactly what the standard tirzepatide headline says. Taking less does not cost less here. For semaglutide it costs considerably more. The headlines need their own warning, because they are the numbers a reader carries away. Neither is a rate anyone pays by default: each card also prints an annual-plan price roughly twice as high next to a discount code, and the arithmetic settles which is which, since 58% off the plan price lands exactly on the advertised figure. No month-to-month rate is published for either compounded product at all. The microdose prices are the unconditional ones, which is why they are the figures to compare, and it is worth sitting with what that means — the only prices here you can rely on are the ones charging you more to take less.

Vs median

$23/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Prices the low dose on its own

Consult

Included in the price

Dietitian

Included

Labs

Not required

Pricing

Check plan terms

Fridays does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

Fridays is the clearest case on this page of the thing this site was built to find. It sells a real, named microdose product — its own nav has a Microdosing tab, the page describes weekly injections or daily oral tablets, and the two products carry plain unconditional monthly prices. It also sells the standard full-dose versions of the same two molecules. Set the two pages beside each other and the microdose semaglutide costs $249 a month against a $117 headline for the ordinary one, and the microdose tirzepatide costs exactly what the ordinary tirzepatide costs. Taking less does not cost less here; for semaglutide it costs more than twice as much. The headline figures deserve their own warning, because they are the numbers a reader will carry away. Neither is a rate anybody pays by default: each sits on a card that also prints an annual-plan price roughly twice as high and a discount code, and the arithmetic confirms which is which — 58% off $279 is $117 to the dollar. What is not published anywhere is a month-to-month rate for either compounded product. The microdose prices, by contrast, are unconditional, which is the reason this row is ranked on them.

The microdose semaglutide costs more than twice the seller's own semaglutide headline.

• Both headline figures are discount-code rates on an annual plan; the plan price is roughly double.
• No month-to-month rate is published for either compounded product.

Fridays is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Low dose vs full dose
• The true annual cost of a plan
• What a flat price costs at a low dose